This study is a multi-site, single-arm, ambispective, observational study of subject satisfaction, after successful bilateral LASIK surgery. Subjects will be assessed 12+ months post-operatively. Clinical evaluations will include administration of the OSDI, modified PROWL, and dry eye questionnaires.

Start Date01 Nov 2024

Sponsor / Collaborator

OVO LASIK + LENS LLC

100 Clinical Results associated with OVO LASIK + LENS LLC

0 Patents (Medical) associated with OVO LASIK + LENS LLC

Literatures (Medical) associated with OVO LASIK + LENS LLC

01 Sep 2022·Journal of Cataract and Refractive SurgeryQ2 · MEDICINE

Clinical and refractive outcomes after topography-guided refractive surgery planned using Phorcides surgery planning software

Q2 · MEDICINE

Article

Author: Mann, Paul M ; Stonecipher, Karl ; Lobanoff, Mark ; Stulting, R Doyle ; Wexler, Stephen ; Potvin, Richard

Purpose:To evaluate prospectively the clinical outcomes of topography-guided laser in situ keratomileusis (LASIK) surgery performed with Contoura Vision using the Wavelight excimer laser and planned with the Phorcides Analytical Engine.Setting:Four clinical practices in the U.S.Design:Prospective single-arm interventional study.Methods:130 eyes of 65 patients with myopia or myopic astigmatism were enrolled in a prospective study of visual and refractive outcomes after treatment with Contoura Vision using the Wavelight EX500 excimer laser to achieve optimal distance vision. At 3 months postoperatively, uncorrected distance visual acuity (UDVA), manifest refraction, and corrected distance visual acuity (CDVA) were measured and compared with previously published studies.Results:At 3 months postoperatively, 100%, 89%, and 28% of eyes achieved UDVA of 20/20, 20/15, and 20/12.5 or better, respectively. 92% of eyes had postoperative UDVA equal to or better than their preoperative CDVA. Postoperative CDVA was equal to, 1 line better, or 2 lines better than the preoperative CDVA in 53%, 40%, and 6% of eyes, respectively. Only 1 eye lost 1 line of CDVA, and no eyes lost more than 1 line of CDVA. A statistically significant decrease was noted in subjective visual complaints, including glare, halos, difficulty driving at night, reading difficulty, starbursts, fluctuation in vision, and light sensitivity.Conclusions:The Phorcides Analytical Engine can be used to optimize visual outcomes for the correction of myopia and myopic astigmatism.

100 Deals associated with OVO LASIK + LENS LLC

100 Translational Medicine associated with OVO LASIK + LENS LLC

Corporation Tree

Boost your research with our corporation tree data.

view full example data

Pipeline

Pipeline Snapshot as of 09 Dec 2025

No data posted

Deal

Boost your decision using our deal data.

view full example data

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Profit

Explore the financial positions of over 360K organizations with Synapse.

view full example data

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.

view full example data

Investment

Gain insights on the latest company investments from start-ups to established corporations.

view full example data

Financing

Unearth financing trends to validate and advance investment opportunities.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

OVO LASIK + LENS LLC

Overview

Related

Corporation Tree

Pipeline

Pipeline Snapshot as of 09 Dec 2025

Deal

Translational Medicine

Profit

Grant & Funding(NIH)

Investment

Financing